Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus TAS-102 for refractory metastatic colorectal cancer
ChiCTR2300071752Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of regorafenib and trifluridine + tipiracil in metastatic colorectal adenocarcinoma (mCRC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: progression-free survival. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
regorafenibtrifluridine + tipiracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2300071752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071752.